TY - JOUR
T1 - Safety of carbon dioxide extract from Cannabis sativa L. as a novel food pursuant to Regulation (EU) 2015/2283
AU - Turck, Dominique
AU - Bohn, Torsten
AU - Cámara, Montaña
AU - Castenmiller, Jacqueline
AU - De Henauw, Stefaan
AU - Jos, Ángeles
AU - Maciuk, Alexandre
AU - Mangelsdorf, Inge
AU - McNulty, Breige
AU - Naska, Androniki
AU - Pentieva, Kristina
AU - Siani, Alfonso
AU - Thies, Frank
AU - Aguilera-Gómez, Margarita
AU - Cubadda, Francesco
AU - Frenzel, Thomas
AU - Knutsen, Helle Katrine
AU - van Loveren, Henk
AU - McArdle, Harry J.
AU - Moldeus, Peter
AU - Neuhäuser-Berthold, Monika
AU - Schlatter, Josef Rudolf
AU - Siskos, Alexandros
AU - Trezza, Viviana
AU - Albert, Océane
AU - Beneventi, Elisa
AU - Laganaro, Marcello
AU - Nuin Garciarena, Irene
AU - Rossi, Annamaria
AU - Berrio Cruz, Sebastian
AU - Seminati, Francesca
AU - Magani, Maura
AU - Hirsch-Ernst, Karen Ildico
AU - EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)
N1 - © 2026 European Food Safety Authority. EFSA Journal published by Wiley‐VCH GmbH on behalf of European Food Safety Authority.
PY - 2026/3/30
Y1 - 2026/3/30
N2 - Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on a carbon dioxide (CO2) extract from industrial hemp varieties of the plant Cannabis sativa L. as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is proposed to be used in food supplements at maximum use levels ranging from 1.12 mg/day for children above 3 years of age to 3.60 mg/day for adults, excluding pregnant and lactating women. The NF contains cannabidiol (CBD) as well as other cannabinoids. The Panel notes that a substantial proportion of the NF remains uncharacterised. Stability and toxicological tests submitted by the applicant were performed with a material different from the NF under assessment, as it was produced using a different production process (i.e. isopropanol (IPA)-based extraction instead of CO2 supercritical extraction), potentially resulting in different compositional data. Therefore, the absence of adequate stability and of toxicological studies performed with a representative test item prevents the Panel from drawing conclusions on the safety assessment of the NF. Additionally, no data were provided by the applicant to address the safety of the NF in the general population above 3 years of age. Therefore, the safety of the NF under the proposed conditions of use cannot be established.
AB - Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on a carbon dioxide (CO2) extract from industrial hemp varieties of the plant Cannabis sativa L. as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is proposed to be used in food supplements at maximum use levels ranging from 1.12 mg/day for children above 3 years of age to 3.60 mg/day for adults, excluding pregnant and lactating women. The NF contains cannabidiol (CBD) as well as other cannabinoids. The Panel notes that a substantial proportion of the NF remains uncharacterised. Stability and toxicological tests submitted by the applicant were performed with a material different from the NF under assessment, as it was produced using a different production process (i.e. isopropanol (IPA)-based extraction instead of CO2 supercritical extraction), potentially resulting in different compositional data. Therefore, the absence of adequate stability and of toxicological studies performed with a representative test item prevents the Panel from drawing conclusions on the safety assessment of the NF. Additionally, no data were provided by the applicant to address the safety of the NF in the general population above 3 years of age. Therefore, the safety of the NF under the proposed conditions of use cannot be established.
KW - CBD
KW - Cannabis sativa
KW - cannabidiol
KW - cannabinoids
KW - food supplement
KW - hemp extract
KW - novel food
UR - https://www.scopus.com/pages/publications/105035621938
UR - https://pubmed.ncbi.nlm.nih.gov/42016299/
U2 - 10.2903/j.efsa.2026.10004
DO - 10.2903/j.efsa.2026.10004
M3 - Comment/debate
C2 - 42016299
AN - SCOPUS:105035621938
SN - 1831-4732
VL - 24
JO - EFSA Journal
JF - EFSA Journal
IS - 3
M1 - e10004
ER -